IDXX analyst estimates
Idexx Laboratories (IDXX) analyst ratings, the average price target and its range, and every firm's latest call.
IDXX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 27, 2026 | UBS | Idexx Laboratories price target lowered to $627 from $670 at UBS | $627.00 |
| Oct 16, 2026 | Goldman Sachs | Idexx Laboratories initiated with a Buy at Goldman Sachs | $740.00 |
| Aug 11, 2026 | Barclays | Idexx Laboratories price target lowered to $710 from $800 at Barclays | $710.00 |
| Jul 27, 2026 | UBS | Idexx Laboratories price target lowered to $620 from $640 at UBS | $620.00 |
| Apr 28, 2026 | UBS | Idexx Laboratories price target lowered to $640 from $730 at UBS | $640.00 |
| Feb 9, 2026 | Piper Sandler | Idexx Laboratories price target lowered to $750 from $775 at Piper Sandler | $750.00 |
| Feb 5, 2026 | Barclays | Idexx Laboratories price target lowered to $800 from $850 at Barclays | $800.00 |
| Feb 3, 2026 | BTIG | Idexx Laboratories price target lowered to $800 from $830 at BTIG | $800.00 |
| Feb 3, 2026 | UBS | Idexx Laboratories price target lowered to $730 from $750 at UBS | $730.00 |
| Dec 8, 2025 | Barclays | Idexx Laboratories initiated with an Overweight at Barclays | $850.00 |
| Nov 4, 2025 | Jefferies | IDEXX Laboratories (IDXX) PT Raised to $830 at Jefferies | $830.00 |
| Nov 4, 2025 | BTIG | Idexx Laboratories price target raised to $830 from $785 at BTIG | $830.00 |
| Nov 4, 2025 | UBS | Idexx Laboratories price target raised to $750 from $710 at UBS | $750.00 |
| Nov 4, 2025 | Morgan Stanley | Idexx Laboratories price target raised to $805 from $765 at Morgan Stanley | $805.00 |
| Nov 3, 2025 | Leerink Partners | Idexx Laboratories price target raised to $785 from $745 at Leerink | $785.00 |
- 9 firms rate IDXX: 5 buy, 4 hold, 0 sell.
- The average price target is $692.33 from 3 analysts, from $627.00 to $740.00.
Updated 2026-11-02 19:10 UTC